Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

287
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
287
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

730
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
730
Atherosclerosis IV: Nursing Management01:23

Atherosclerosis IV: Nursing Management

329
Nursing management for a patient with arteriosclerosis involves a comprehensive approach focusing on lifestyle modification, disease monitoring, education, and symptomatic care. Here is an overview of effective nursing strategies:Assessment and Monitoring: Initial and ongoing assessments are crucial. Nurses must document the patient's medical history, including any hypertension, diabetes, hyperlipidemia, and other cardiovascular diseases. Assessments also cover family history and lifestyle...
329
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

200
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
200
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

211
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
211
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

416
Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
416

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

PREVENT-ASCVD in the 2026 Dyslipidemia Guidelines.

Journal of clinical lipidology·2026
Same author

Cholesterol Perceptions and Preferences Among Young Adults: A Survey of U.S. Adults Aged 30 to 39 Years.

JACC. Advances·2026
Same author

Correction to: 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.

Circulation·2026
Same author

Functional, molecular, and digital measurements of biological age.

The Journal of clinical investigation·2026
Same author

Clinical Guidelines, Market Forces, and Health Disparities.

Circulation·2026
Same author

New Dyslipidemia Guideline Expands Treatment Options and Risk Assessment in Patients With Diabetes and Chronic Kidney Disease.

Journal of the American College of Cardiology·2026

Related Experiment Video

Updated: Jan 6, 2026

Quantification of Atherosclerosis in Mice
06:59

Quantification of Atherosclerosis in Mice

Published on: June 12, 2019

39.9K

Can atherosclerosis be cured?

John T Wilkins1, Samuel S Gidding2, Jennifer G Robinson3

  • 1Departments of Medicine (Cardiology) and Preventive Medicine, Northwestern University Feinberg School of Medicine Chicago, IL.

Current Opinion in Lipidology
|October 9, 2019
PubMed
Summary
This summary is machine-generated.

Lowering LDL-cholesterol (LDL-C) in early adulthood can regress atherosclerosis. Further research is needed to confirm if this approach prevents later-life atherosclerotic cardiovascular disease (ASCVD) events and death.

More Related Videos

Quantitative Analysis of Cellular Composition in Advanced Atherosclerotic Lesions of Smooth Muscle Cell Lineage-Tracing Mice
09:06

Quantitative Analysis of Cellular Composition in Advanced Atherosclerotic Lesions of Smooth Muscle Cell Lineage-Tracing Mice

Published on: February 20, 2019

8.7K
A Model of Disturbed Flow-Induced Atherosclerosis in Mouse Carotid Artery by Partial Ligation and a Simple Method of RNA Isolation from Carotid Endothelium
11:00

A Model of Disturbed Flow-Induced Atherosclerosis in Mouse Carotid Artery by Partial Ligation and a Simple Method of RNA Isolation from Carotid Endothelium

Published on: June 22, 2010

29.6K

Related Experiment Videos

Last Updated: Jan 6, 2026

Quantification of Atherosclerosis in Mice
06:59

Quantification of Atherosclerosis in Mice

Published on: June 12, 2019

39.9K
Quantitative Analysis of Cellular Composition in Advanced Atherosclerotic Lesions of Smooth Muscle Cell Lineage-Tracing Mice
09:06

Quantitative Analysis of Cellular Composition in Advanced Atherosclerotic Lesions of Smooth Muscle Cell Lineage-Tracing Mice

Published on: February 20, 2019

8.7K
A Model of Disturbed Flow-Induced Atherosclerosis in Mouse Carotid Artery by Partial Ligation and a Simple Method of RNA Isolation from Carotid Endothelium
11:00

A Model of Disturbed Flow-Induced Atherosclerosis in Mouse Carotid Artery by Partial Ligation and a Simple Method of RNA Isolation from Carotid Endothelium

Published on: June 22, 2010

29.6K

Area of Science:

  • Cardiovascular Medicine
  • Preventive Cardiology
  • Lipid Metabolism

Background:

  • Apolipoprotein B lipoproteins are fundamentally causal in atherosclerosis development.
  • Elevated LDL-cholesterol (LDL-C) and non-HDL-cholesterol in early adulthood predict accelerated subclinical atherosclerosis and future ASCVD events.
  • Evidence indicates intensive LDL-C lowering can regress atherosclerosis in earlier stages.

Purpose of the Study:

  • To review evidence supporting interventions for preventing atherosclerosis and ASCVD events.
  • To identify future research priorities in atherosclerosis prevention.

Main Methods:

  • Review of extensive epidemiologic, animal, and human data on LDL-C and atherosclerosis.
  • Analysis of current evidence on interventions to lower LDL-C.
  • Identification of research gaps and future trial designs.

Main Results:

  • Strong evidence links LDL-C to atherosclerosis development and progression.
  • Early and intensive LDL-C lowering demonstrates potential for atherosclerosis regression.
  • The causal role of LDL-C in ASCVD is well-established.

Conclusions:

  • Lowering LDL-C earlier in life may regress early atherosclerosis.
  • Future trials should evaluate if early LDL-C reduction eradicates later-life ASCVD events and death.
  • A strategy focused on 'curing' atherosclerosis offers the most effective approach to reduce the global burden of the disease.